Abstract: The present disclosure provides methods for generating cortical excitatory neurons, cortical excitatory neurons generated by such methods, and composition comprising such cells. The present disclosure also provides uses of the cortical excitatory neurons and composition comprising thereof for preventing and/or treating neurodegenerative disorders.

Abstract: The present disclosure relates to the use of iron chelation to prevent and/or treat leptomeningeal metastasis. In certain embodiments, the present disclosure provides methods for the prevention and/or treatment of leptomeningeal metastasis that include the administration of an iron chelator to a subject. The present disclosure further provides kits for performing such methods.

Abstract: The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor antigens. It relates to cells comprising: an antigen-recognizing receptor (e.g., a chimeric antigen receptor, a TCR, or a TCR like fusion molecule); and a gene disruption of a CD70 locus. The gene disruption of the CD70 locus can improve the activity and/or efficiency of the cells.

Abstract: The present disclosure provides compounds, complexes, compositions, and methods for the detection of cancer. Specifically, the compounds, complexes, compositions of the present technology include pH (low) insertion peptides. Also disclosed herein are methods of using the complexes and compositions of the present technology in diagnostic imaging to detect cancer in a subject.

Abstract: The present disclosure provides novel dominant negative Fas polypeptides comprising a first modification in the cytoplasmic domain and a second modification in the N-terminal region of human Fas. The present disclosure also provides cells comprising such novel dominant negative Fas polypeptides and an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)). Also provided are uses of the cells for treatment, e.g., for treating tumors and pathogen infections.

Abstract: The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to cells comprising a c-Kit mutant, e.g., a c-Kit mutant comprising an activating mutation. The cells can further comprise an antigen-recognizing receptor (e.g., a chimeric antigen receptors (CAR) or a T cell receptors (TCR)). The presently disclosed subject matter relates to the use of cells for treatment, e.g., treating cancers.

Abstract: The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.

Abstract: The presently disclosed subject matter provides cells and compositions for improved immunotherapy and methods of using such cells and compositions. It relates to cells comprising a ligand-recognizing receptor (e.g., an antigen-recognizing receptor, e.g., a chimeric antigen receptor (CAR) or a T-cell Receptor (TCR)) and an IgG-degrading enzyme or a fragment thereof. The IgG-degrading enzyme rapidly cleaves IgG. The IgG-degrading enzyme serves as a biomolecular shield against the host humoral response. The cells have increased resistance to host humoral response (e.g., an antibody-driven host humoral response), which allows for prolonged persistence of the cells, leading to enhanced activity of the cells.

Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD371 and cells comprising such CD371-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD371-targeted antigen-recognizing receptors for treatment.

Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to CD371 and methods of using such antibodies or antigen-binding fragments thereof same.

Abstract: The presently disclosed subject matter provides methods and compositions for enhancing immune responses toward tumor and pathogen antigens. It relates to fusion polypeptide that can be expressed in cells (e.g., immunoresponsive cells comprising an antigen-recognizing receptor) to improve the activity and/or efficiency of the cells. In certain embodiments, the fusion polypeptide comprises an extracellular domain and a transmembrane domain of a co-stimulatory ligand, and an intracellular domain of a co-stimulatory molecule.

Abstract: UDPG shows tumor-specific inhibition of PRPP and this suggests that this action might prove to be useful in combination therapy with inhibitors of purine and pyrimidine nucleotide synthesis in various rescue regimens. High levels of PRPP in tumors were greatly affected by treatment with UDPG.

Abstract: An imaging apparatus with a flexible light guide which a surgeon can easily manipulate within the patient to control the field of view. Specifically, a scintillator receives radiation rays and converts these radiation rays into light signals at a position inside the body. A flexible bundle of optical fibers optically connected to the scintillator, channels the light signals from the scintillator to a position sensitive light signal detector located outside the body. The position sensitive light signal detector creates a digital signal to relay the position information about the detected event to a computer which accumulates these digital signals, converts these digital signals into images and displays the images.

Abstract: The present invention relates to a closed wound drainage system with a clearing port connected to the system, having a permeable membrane for sealable passage of a needle therethrough for injection of fluid into the system in order to flush the system without opening the system. The clearing port may also be used to withdraw fluid samples from the system for laboratory analysis without contaminating the system or the sample during the withdrawal procedure. The present invention also relates to a method for sterile clearing of obstructions in a closed wound drainage system.

Abstract: The present invention provides a method for decreasing the bodily content of uric acid in a subject which comprises administrating to the subject an effective content-decreasing amount of a barbiturate compound mono-substituted at the carbon-5 position.The invention also provides a pharmaceutical composition and a method for treating disorders of uric acid metabolism and resulting ailments in a subject.

Abstract: Apparatus are described which is useful in continuous operation of magnetic resonance imaging studies. The apparatus permits examination of subjects without repositioning of the subject and produces more accurate studies than previously possible.

Abstract: A surgically implantable, multi-lumen, high profile mammary implant includes a first, flexible, lumen at least partly and filled with a soft gel material and having a front wall approximating the shape of a human breast and a second, firmer flexible lumen elastic within the first lumen and connected thereto solely at the rear wall of the first lumen. The second lumen has a volume which is less than the volume of the first lumen and at least partly filled with a second soft gel material. A third lumen preferably inflatably surrounds the first lumen and is inflated with saline solution.

Abstract: This invention relates to a method for the non-surgical treatment of tumors. The method of this invention involves the use of shock waves to effect subcellular destruction of tumor cells, to alter their tumorigenic potential, and to suppress tumor growth.

Abstract: A surgically implantable, multi-lumen, high profile mammary implant includes a first, flexible, elastic lumen at least partly filled with a soft gel material and having a front wall approximating the shape of a human breast and a second, firmer, flexible lumen within the first lumen and connected thereto solely at the rear wall of the first lumen. The second lumen has a volume which is less than the volume of the first lumen and is at least partly filled with a second soft gel material. A third lumen preferably inflatably surrounds the first lumen and is inflated with saline solution.

Abstract: An N-path filter has a number N of parallel resistive-capacitive filter sections. A switching arrangement connects each filter section periodically into an input signal path through the filter. The switching arrangement also triggers a sample and hold network to sample the filtered input signal for a portion of the time each filter section is connected into the input signal path through the filter and then hold the sampled, filtered input signal. The sampling time is preferably selected to be an initial portion of the time each filter section is connected as the signal path through the filter when variations in the charging rates of the capacitors in the filter sections have the least effect. The sampled N-path filter technique thus reduces the need to match the filter section components.